PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma

  • Elena Zamagni
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Cristina Nanni
    2Institute of Nuclear Medicine, Bologna University School of Medicine, Bologna, Italy.
  • Katia Mancuso
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Paola Tacchetti
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Annalisa Pezzi
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Lucia Pantani
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Beatrice Zannetti
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Ilaria Rambaldi
    2Institute of Nuclear Medicine, Bologna University School of Medicine, Bologna, Italy.
  • Annamaria Brioli
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Serena Rocchi
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Carolina Terragna
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Marina Martello
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Giulia Marzocchi
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Enrica Borsi
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Ilaria Rizzello
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Stefano Fanti
    2Institute of Nuclear Medicine, Bologna University School of Medicine, Bologna, Italy.
  • Michele Cavo
    1“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.

書誌事項

公開日
2015-09-30
DOI
  • 10.1158/1078-0432.ccr-15-0396
公開者
American Association for Cancer Research (AACR)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>Purpose: To evaluate the role of 18F-FDG PET/CT in 282 symptomatic multiple myeloma patients treated up-front between 2002 and 2012.</jats:p> <jats:p>Experimental Design: All patients were studied by PET/CT at baseline, during posttreatment follow-up, and at the time of relapse. Their median duration of follow-up was 67 months.</jats:p> <jats:p>Results: Forty-two percent of the patients at diagnosis had &gt;3 focal lesions, and in 50% SUVmax was &gt;4.2; extramedullary disease was present in 5%. On multivariate analysis, ISS stage 3, SUVmax &gt;4.2, and failure to achieve best complete response (CR) were the leading factors independently associated with shorter progression-free survival (PFS) and overall survival (OS). These 3 variables were used to construct a prognostic scoring system based on the number of risk factors. After treatment, PET/CT negativity (PET-neg) was observed in 70% of patients, whereas conventionally defined CR was achieved in 53%. Attainment of PET-neg favorably influenced PFS and OS. PET-neg was an independent predictor of prolonged PFS and OS for patients with conventionally defined CR. Sixty-three percent of patients experienced relapse or progression; in 12%, skeletal progression was exclusively detected by systematic PET/CT performed during follow-up. A multivariate analysis revealed that persistence of SUVmax &gt;4.2 following first-line treatment was independently associated with exclusive PET/CT progression.</jats:p> <jats:p>Conclusions: PET/CT combined with ISS stage and achievement or not of CR on first-line therapy sorted patients into different prognostic groups. PET/CT led to a more careful evaluation of CR. Finally, in patients with persistent high glucose metabolism after first-line treatment, PET/CT can be recommended during follow-up, to screen for otherwise unidentifiable progression. Clin Cancer Res; 21(19); 4384–90. ©2015 AACR.</jats:p>

収録刊行物

  • Clinical Cancer Research

    Clinical Cancer Research 21 (19), 4384-4390, 2015-09-30

    American Association for Cancer Research (AACR)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ